| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/ARD.2010.140129 |
| P8608 | Fatcat ID | release_z3prfgj7qjdcpp7gxzjy6cymie |
| P698 | PubMed publication ID | 21551512 |
| P50 | author | Merete Lund Hetland | Q56223933 |
| P2093 | author name string | Mikkel Ostergaard | |
| Annette Hansen | |||
| Ulrik Tarp | |||
| Lene Dreyer | |||
| Tove Lorenzen | |||
| Niels Steen Krogh | |||
| Bente Glintborg | |||
| Michael Sejer Hansen | |||
| all departments of rheumatology in Denmark | |||
| Heidi Foged | |||
| Henrik Christian Leffers | |||
| Martin Skov Jacobsen | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| rheumatoid arthritis | Q187255 | ||
| tocilizumab | Q425154 | ||
| P304 | page(s) | 1216-1222 | |
| P577 | publication date | 2011-05-08 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry | |
| P478 | volume | 70 |
| Q58800375 | A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences |
| Q47367453 | A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. |
| Q34752154 | Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. |
| Q92857546 | Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register |
| Q35974381 | Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry |
| Q27021115 | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| Q34656204 | Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity |
| Q34067792 | Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies |
| Q30956564 | Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt |
| Q61810043 | Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study |
| Q39885959 | Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study |
| Q50445051 | Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. |
| Q90582460 | Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q35135754 | Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry |
| Q46894147 | Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry |
| Q41693369 | Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register |
| Q52653996 | Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. |
| Q64053097 | Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study |
| Q64062693 | Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study |
| Q36267465 | EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry |
| Q40735887 | Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry |
| Q37587403 | Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study |
| Q47567355 | Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound |
| Q35258244 | Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry |
| Q64999881 | High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis. |
| Q37965754 | Immunotherapeutic implication of IL-6 blockade |
| Q47130490 | Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry |
| Q33849223 | Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles |
| Q56969640 | Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries |
| Q50964701 | Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. |
| Q28073763 | New pharmacological strategies in rheumatic diseases |
| Q47917968 | Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience |
| Q48302611 | Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up |
| Q86934388 | Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study |
| Q90415663 | Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817) |
| Q27024465 | Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
| Q50674920 | Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. |
| Q27692641 | Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine |
| Q35728708 | Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q47861250 | Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. |
| Q30769719 | Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data |
| Q30612998 | Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data |
| Q43444262 | Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. |
| Q42578542 | Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis |
| Q38305522 | Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| Q47645345 | Sex and Management of Rheumatoid Arthritis |
| Q48933199 | Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japa |
| Q35922117 | Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns |
| Q51741859 | Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. |
| Q30962462 | Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic |
| Q33775593 | The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice |
| Q38030974 | The role of tocilizumab in the management of rheumatoid arthritis |
| Q64247906 | Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies |
| Q35724900 | Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions |
| Q26772699 | Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells |
| Q38125240 | Update on the use of abatacept for the treatment of rheumatoid arthritis. |
| Q30863740 | Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study |
Search more.